clinical-stage biotech Archives

Conceptual Serina Therapeutics laboratory illustration with neurons, drug-delivery imagery and a display highlighting a potential 2027 clinical milestone.

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

by John F. Heerdink, Jr. 5 days ago 153Views 0Likes

As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself. Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…

Futuristic biotech illustration featuring a glowing digital bull, rising market arrows, and research pathways labeled Disc Medicine, Arcutis and Parabilis leading toward a biotechnology innovation hub.

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

by John F. Heerdink, Jr. October 19, 2026 465Views 0Likes

A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector. October 19, 2026 Biotechnology investors are being offered three…

Eupraxia Pharmaceuticals illustration showing a dart hitting a 120-patient enrollment target, a December data calendar, and the EPRX stock ticker.

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

by John F. Heerdink, Jr. October 16, 2026 463Views 0Likes

With 120 patients enrolled in its Phase 2b study, Eupraxia’s drug-delivery platform moves toward a consequential clinical test. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), the story is becoming less about recruiting patients and more about what their results might reveal.…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 420Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

by John F. Heerdink, Jr. October 3, 2026 452Views 0Likes

Parabilis Medicines, Inc. (NASDAQ: PBLS) entered public markets with the kind of financial runway, strategic endorsement and clinical ambition that tends to make biotech investors sit up straighter in their Aeron chairs. The Cambridge-based clinical-stage company is pursuing a deceptively simple proposition: use…

Business analysts review Eupraxia Pharmaceuticals’ EP-104GI clinical data, including symptom reduction and histological-response visuals, alongside an investment calendar highlighting the anticipated December 2026 RESOLVE trial milestone.

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

by John F. Heerdink, Jr. October 2, 2026 788Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 480Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 582Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 583Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 561Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Tag: clinical-stage biotech

Serina Therapeutics: A Parkinson’s Bet Where Delivery Is the Message -( $ABBV $SER )

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

Eupraxia Pharmaceuticals Hits RESOLVE Enrollment Target as December EoE Data Come Into Focus -( $EPRX $XBI $IBB )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

The Biotech IPO Window Is Open, and Parabilis Medicines Walked Through With $770 Million -( $ADRX $BRVE $ETRA $KLRA $JNJ $PBLS $REGN )

Eupraxia’s One-Year EoE Data Draw Fresh Analyst Attention Ahead of December Catalyst – ( $EPRX $IBB $SNY $XBI )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Your Guide To Staying Informed In The Markets